Nationwide evaluation of treatment outcomes and survival of patients with non-tuberculous mycobacterial pulmonary disease
The International Journal of Tuberculosis and Lung Disease · 2024
DOI: 10.5588/ijtld.24.0068 ↗Kurz gefasst
Fachartikel in der Zeitschrift The International Journal of Tuberculosis and Lung Disease, 2024. Verfasst von M J Makek und 11 weiteren Autor:innen. Beteiligte Einrichtung: University of Zagreb, School of Medicine, Zagreb, Croatia;, Department for Respiratory Diseases, University Hospital Centre Zagreb, Zagreb, Croatia. Hauptthemen laut MEDLINE: Mycobacterium Infections, Nontuberculous. Die Arbeit wurde bisher 5-mal zitiert (Crossref).
Abstract (Originalsprache)
BACKGROUND
Treatment outcomes and long-term survival of non-tuberculous mycobacterial pulmonary disease (NTM-PD) in a real-world setting are difficult to assess, especially for species other than Mycobacterium avium complex (MAC).
METHODS
This was a retrospective cohort study on all Croatian residents with respiratory NTM isolates from 2006 to 2015, with follow-up to 2020.
RESULTS
Therapy was started in 98/137 (71.5%) of patients, significantly more often in patients with fibrocavitary disease and/or sputum smear positivity. Unsuccessful treatment outcomes were recorded in 39/98 (39.8%) patients (14 deaths and 25 treatment failures). One-year and 5-year all-cause mortality were respectively 18.2% and 37.6%. Guideline-based treatment (GBT) was started in 50/98 (51%) of treated patients and followed for the recommended duration in 35.7% (35/98). This resulted in a higher chance of cure (OR 3.79, 95% CI 1.29 to 11.1; P = 0.012) than inadequately treated/untreated patients. For Mycobacterium xenopi disease, high cure rates (>80%) were achieved both with GBT and non-GBT treatment regimens.
CONCLUSION
Guideline-based therapy resulted in a four-time higher chance of being cured. The impact of GBT on treatment outcomes was clear for MAC disease, but no apparent effect was observed for patients with M. xenopi disease.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- University of Zagreb, School of Medicine, Zagreb, Croatia;, Department for Respiratory Diseases, University Hospital Centre Zagreb, Zagreb, Croatia.
- Department for Respiratory Diseases, University Hospital Centre Zagreb, Zagreb, Croatia.
- Division of Molecular Medicine, Laboratory of Molecular Virology and Bacteriology, Ruder Boskovic Institute, Zagreb, Croatia.
- University of Zagreb, School of Medicine, Zagreb, Croatia;, National Mycobacteria Reference Laboratory, Croatian National Institute of Public Health, University of Zagreb, School of Medicine, Zagreb, Croatia.
- Special Hospital for Respiratory Diseases Rockefellerova, Zagreb, Croatia.
- Department for Radiology, University Hospital Centre Zagreb, Zagreb, Croatia.
Zitieren
APA
Makek, M. J., Glodic, G., Sabol, I., Zmak, L., Samarzija, M., Sola, A., Marusic, A., Marekovic, I., Bulat, L. K., Corak, L., Obrovac, M., & van Ingen, J. (2024). Nationwide evaluation of treatment outcomes and survival of patients with non-tuberculous mycobacterial pulmonary disease. The International Journal of Tuberculosis and Lung Disease. https://doi.org/10.5588/ijtld.24.0068
Vancouver
Makek MJ, Glodic G, Sabol I, Zmak L, Samarzija M, Sola A, et al. Nationwide evaluation of treatment outcomes and survival of patients with non-tuberculous mycobacterial pulmonary disease. The International Journal of Tuberculosis and Lung Disease. 2024. doi:10.5588/ijtld.24.0068
BibTeX
@article{Makek2024,
author = {Makek, M J and Glodic, G and Sabol, I and Zmak, L and Samarzija, M and Sola, A and Marusic, A and Marekovic, I and Bulat, L K and Corak, L and Obrovac, M and van Ingen, J},
title = {Nationwide evaluation of treatment outcomes and survival of patients with non-tuberculous mycobacterial pulmonary disease},
journal = {The International Journal of Tuberculosis and Lung Disease},
year = {2024},
doi = {10.5588/ijtld.24.0068}
}
EUVIMED